Name: Prevention and Early Detection of Human Tumours - Second Edition de Siamak Haghdoost Ellen He(Ks Omniscriptum Publishing) (en Inglés)
SKU: 62459578
Price: 304293.00 COP
Availability: InStock
Author: Skog Sven,He Ellen,Haghdoost Siamak

portada Prevention and Early Detection of Human Tumours - Second Edition de Siamak Haghdoost Ellen He(Ks Omniscriptum Publishing) (en Inglés)

Prevention and Early Detection of Human Tumours - Second Edition de Siamak Haghdoost Ellen He(Ks Omniscriptum Publishing) (en Inglés)

Formato

Libro Físico

Editorial

Ks Omniscriptum Publishing

Autor

Skog Sven,He Ellen,Haghdoost Siamak

Idioma

Inglés

Encuadernación

Tapa Blanda

ISBN13

9786206166474

Prevention and Early Detection of Human Tumours - Second Edition de Siamak Haghdoost Ellen He(Ks Omniscriptum Publishing) (en Inglés)

Skog Sven,He Ellen,Haghdoost Siamak (Autor) · Ks Omniscriptum Publishing · Tapa Blanda

Libro Nuevo Importado

Envío: 20 a 24 días háb.

$ 608.586$ 304.293

-50%

Costos de importación incluídos en el precio ✅

Libro Nuevo

Quedan 10 unidades

$ 304.293

¡Envío Gratis! Llega entre el 22 Sep y el 29 Sep a Bogota, Cundinamarca. Seleccionar ubicación

Agregar a lista de deseos

Reseña del libro "Prevention and Early Detection of Human Tumours - Second Edition de Siamak Haghdoost Ellen He(Ks Omniscriptum Publishing) (en Inglés)"

In 2014 World Health Organization (WHO) reported that during the next 25 years the number of cancer cases would increase by about 70% worldwide. In order to deal with this dramatic increase, WHO suggested to focus on prevention, early detection and early treatment of human tumour by health screening. We have worked on this topic for more than 30 years resulting in detection of precancerous lesions to enable early intervention in clinical oncology, preventing cancer progression and reducing mortality. A new model has been developed - Prevention, Early Detection and Early Treatment Tumourigenesis - based on oxidative stress (8-oxo-dG) and a reliable tumour proliferation biomarker (human thymidine kinase 1 (HTK1) in serum (STK1). STK1 assay by IgY polyclonal antibody against HTK1 is able to discover invisible malignant tumours before the appearance of tumour loci in modern imaging. It is not only in the clinical evaluation of prognosis, recurrence risk, and survival in cancer patients but also for early tumour screening especially, showing that people with elevated STK1 levels in their blood have a 3-5 times higher risk to develop malignancy within 11 years.